ETMExperimental and Therapeutic Medicine1792-09811792-1015D.A. SpandidosETM-0-0-1077310.3892/etm.2021.10773ReviewAdrenal ganglioneuroma: Prognostic factors (Review)SandruFlorica12DumitrascuMihai Cristian34PetcaAida35CarsoteMara67PetcaRazvan-Cosmin89OproiuAna Maria1011GhemigianAdina67Department of Dermatology, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, RomaniaDepartment of Dermatology, ‘Elias’ Emergency Hospital, 011461 Bucharest, RomaniaDepartment of Obstetrics and Gynecology, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, RomaniaDepartment of Obstetrics and Gynecology, University Emergency Hospital of Bucharest, 050098 Bucharest, RomaniaDepartment of Obstetrics and Gynecology, ‘Elias’ Emergency Hospital, 022461 Bucharest, RomaniaDepartment of Endocrinology, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, RomaniaDepartment of Endocrinology, ‘C. I. Parhon’ National Institute of Endocrinology, 011863 Bucharest, RomaniaDepartment of Urology, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, RomaniaDepartment of Urology, ‘Prof. Dr. Theodor Burghele’ Clinical Hospital, 061344 Bucharest, RomaniaDepartment of Plastic and Reconstructive Surgery, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, RomaniaDepartment of Plastic and Reconstructive Surgery, University Emergency Hospital of Bucharest, 050098 Bucharest, RomaniaCorrespondence to: Dr Mihai Cristian Dumitrascu, Department of Obstetrics and Gynecology, ‘Carol Davila’ University of Medicine and Pharmacy, 8 Street Eroii Sanitari, 050474 Bucharest, Romania drdumitrascu@yahoo.com
Abbreviations: ADC, apparent diffusion coefficient; EMT, epithelial-mesenchymal transition; HU, Hounsfield units; I, iodine; IDRF, image defined risk factors; MEN, multiple endocrine neoplasia; mTOR, mechanistic target of rapamycin; MIBG, metaiodobenzylguanidine; NMDAR, anti-N-methyl-D-aspartate receptor; PKB, protein kinase B; ROHHAD(NET) syndrome, rapid obesity with hypoventilation, hypothalamic dysfunction and autonomic dysregulation and neuroendocrine tumor syndrome; TH, tyrosine hydroxylase
Ganglioneuroma, a rare neural crest-derived tumor, exhibits a benign profile in contrast to other neuroblastic tumors (neuroblastoma/ganglioneuroblastoma). Ganglioneuromas can be found anywhere autonomic ganglia are located, mostly abdominal/pelvic sites followed by the adrenal glands (one-third of cases), mediastinum/thorax and cervical area. Affecting especially children more than 10 years of age, Ganglioneuroma is either asymptomatic or may cause local compressive effects; rarely inducing nonspecific abdominal complains or arterial hypertension related to oversecretion of epinephrine/norepinephrine/dopamine. Despite a good prognosis, adrenalectomy is necessary in order to rule out a malignancy. Open procedure represents the standard therapeutic option; alternatively, centers with large laparoscopic pediatric experience and good stratification protocols have reported successful procedures. High uptake of I123-MIBG is associated with a more severe outcome in cases with increased mitotic index. In neuroblastic tumors, neuron-specific enolase >33 ng/ml, age at diagnosis <49 months, and blood vessel invasion indicate a poor prognosis. Concurrent extra-adrenal/adrenal ganglioneuroma is associated with a more severe prognosis; post-surgical complications are more frequent in non-adrenal vs. adrenal ganglioneuroma. Exceptionally, immune-mediated paraneoplastic neurologic syndromes have been reported: anti-N-methyl-D-aspartate receptor encephalitis and opsoclonus-myoclonus-ataxia syndrome. ROHHAD syndrome is the underlying cause in 40-56% of cases of neuroendocrine tumors including ganglioneuroma; 70% of tumors are diagnosed within the first 24 months after hypothalamic obesity onset, associated with a severe prognosis due to hypoventilation, sleep apnea, and dysautonomia. Recently, the PKB/AKT/mTOR/S6 pathway was identified as a tumorigenic pathway in pediatric ganglioneuroma, not in neuroblastoma; mTOR inhibitors are a potential option for pre-operatory tumor shrinkage. Pediatric adrenal ganglioneuroma has a good prognosis if adequately treated; its recognition requires adrenalectomy. Further development of specific biomarkers is needed. In the present article, we aimed to introduce a review of the literature involving adrenal ganglioneuroma based on a practical, multidisciplinary perspective of prognostic factors.
ganglioneuromaadrenal tumoradrenal ganglioneuromaadrenalectomyneuroblastomaadrenal medullaneuroblastic tumorpediatric surgeryneural crest tumoradrenal incidentalomaFunding: No funding was received.1. Introduction
Adrenal tumors in children are associated with a broad range of presentations most of which have an aggressive profile such as neuroblastoma, poorly differentiated pheocromocytoma and adrenocortical carcinoma (1). Mostly benign features are found in pure cystic lesions (2). Neuroblastoma, ganglioneuroma and neuroblastoma-ganglioneuroma (also called ganglioneuroblastoma) originate from neural crest progenitor cells/sympathogonia (including adrenal medulla), so called neuroblastic tumors, together representing the most frequent extracranial solid pediatric tumors. At the end of the aggressive spectrum, there is neuroblastoma, while at the other end exhibiting generally considered benign features there is ganglioneuroma (3). Adrenal medulla is also the origin of pheochromocytomas with different grades of differentiation and associated malignant potential and also composite pheochromocytoma, a distinct rare entity (4,5).
Ganglioneuroma, a benign tumor of neuroblastic type, originates from the autonomous sympathetic nervous system, either central or peripheral; thus, the sites can be anywhere in relationship to the presence of autonomic ganglia such as the adrenals, retroperitoneum, mediastinum/thorax, and cervical area (4,5). Ganglioneuroma is considered to be a tumor with the least aggressive profile among all neuroblastic tumors since it exclusively has mature cells; it is also the rarest tumor of this category (6). One-third of ganglioneuromas are located at the adrenal level (7). Ganglioneuromas are typically found in patients over 10 years of age; they are asymptomatic or they are associated with compressive local effects (7).
Surgery is required when a clear identification of the ganglioneuroma cannot be done in the absence of a post-operative histological report or when the tumor is large or is associated with local compressive symptoms (8). Overall, a very good prognosis is described (8).
The largest meta-analysis concerning ganglioneuroma, regardless of age, was published in 2021 (including published cases on PubMed between 1995 and 2018); they found 364 cases; 65.7% were adults; female predominance (62%); incidental detection in 24.5% of all cases; and most frequent sites were abdomen/pelvis (66.2%) followed by adrenal ganglioneuroma (32.1%). Post-operative complications were the rarest after adrenalectomy (1%) when compared to head, neck and thorax location; and no recurrence was reported confirming the benign behavior independent of age (9).
2. Aim of the review
We aimed to introduce a review of the literature involving adrenal ganglioneuroma based on practical, multidisciplinary perspective of prognostic factors.
This is a narrative, PubMed-based review of literature focused on practical points regarding ganglioneuroma and prognostic factors. We cited 73 papers published within the last 10 years (published between 2021 and 2012). The researched key words in different combinations included ‘ganglioneuroma’, ‘neuroblastoma’, ‘pediatric’, ‘children’, ‘adrenal’, ‘outcome’, ‘prognostic’. The criteria of inclusion were practical and clinical relevance. We only included full length, original, English language published papers with various degrees of statistical power due to the rarity of the tumor.
3. Presentation of an adrenal ganglioneuroma
Adrenal ganglioneuromas usually lack specific signs and symptoms. It has a negative endocrine profile, but it has the potential to mimic other adrenal cancers when it comes to imaging findings; thus, the importance of its removal in order to obtain post-operative pathological identification (10). Non-specific abdominal distention and complaints which are not directly regarded as a marker of poor prognosis have been described; oversecretion of epinephrine/norepinephrine/dopamine is exceptional; also high blood pressure is extremely rarely associated (11,12). Exceptionally, immune-mediated paraneoplasic neurologic syndromes have been reported including: NMDAR (anti-N-methyl-D-aspartate receptor) encephalitis and opsoclonus-myoclonus-ataxia syndrome (13).
At imaging evaluation, a cutoff of 3 cm has been suggested between large and small adrenal ganglioneuroma with respect to different behaviors (14). High uptake of I123-MIBG (metaiodobenzylguanidine) is associated with a poor prognosis as seen in neuroblastomas and ganglioneuromas with increased mitotic index; while some tumors, regardless of whether they are ganglioneuromas or neuroblastomas, are I123-MIBG-negative. In addition, false-positive results are due to focal nodular hyperplasia (15,16).
One study on pediatric and adult ganglioneuromas showed that 27 out of 53 were adrenal tumors. Overall, the age interval was between 1.7 years and 64 years (mean of 31 years), the median tumor size was 8 cm. A negative hormonal profile was confirmed and two-thirds of the adrenal ganglioneuromas were incidentally detected (17). Another large study on 345 subjects with neuroblastic tumors (24.6% were ganglioneuromas and 75.4% were neuroblastomas) demonstrated that the most important factors for malignancy prediction were: A pre-operatory level of serum neuron-specific enolase higher than 33 ng/ml, an age at diagnosis younger than 49 months, and blood vessel invasion (18).
4. Syndromic circumstances
Rapid Obesity with Hypoventilation, Hypothalamic dysfunction and Autonomic Dysregulation and NEuroendocrine Tumor [ROHHAD(NET)] syndrome or ROHHAD syndrome is an exceptional rare syndrome, first described in 2007, with a high risk of fatal outcome in children aged between 2 and 4 years (19,20). It consists of hypothalamic obesity similar with monogenetic obesity syndromes, psychiatric conditions, hypoventilation complicated with pulmonary hypertension, sleep apnea, and dysautonomia following obesity within a few years (21,22). In addition, tumors originating from the neural crest including ganglioneuroma have been reported, indicating that 40-56% of patients develop a neuroendocrine tumor including a ganglioneuroma and 70% of them are detected within the first 24 months after the onset of obesity (23,24). No specific marker is an adequate prognostic predictor under these severe circumstances and the genetic background is still unknown (25). The initial evidence of ROHHAD syndrome is rapidly progressing obesity in a previous healthy child (24).
Limited data concerning the association between pediatric ganglioneuroma and papillary thyroid cancer or multiple endocrine neoplasia (MEN) type 2A syndrome are available to date (26). In addition, a report of Turner syndrome for a patient with ganglioneuroma is probably incidental (27). One girl with constitutional 11q interstitial deletion syndrome was reported with concurrent adrenal neuroblastoma and prevertebral ganglioneuroma (28). A case of a 13-year female with adrenal ganglioneuroma and a syndrome of hereditary spherocytosis was previously published, probably also an accidental association (29). Neurogenic tumors of different locations include a large range of Schwann cell originating tumors with or without neuroblastic differentiation, and ganglioneuromas need to be differentiated from schwannomas or neurofibromas, also associated with classical features of neurofibromatosis type 1 syndrome (30,31). A few cases of gastrointestinal ganglioneuromatosis associated with the presence of neurofibromatosis type 1, MEN type 2B syndrome and Cowden syndrome (PTEN gene mutation) have been reported (32).
5. Extra-adrenal ganglioneuroma
Extra-adrenal ganglioneuroma may be present in a patient as a single neuroblastic tumor or, rarely, synchronously in two different locations; concurrent adrenal and non-adrenal ganglioneuromas are associated with a more severe prognosis than a single adrenal mass (33). Cervical ganglioneuromas originate from Schwann cells of cervical sympathetic ganglia or are related to vagus/hypoglossal nerves; they need to be differentiated from head and neck tumors of soft tissue (34). The confirmation comes after tumor removal and consecutive histological report, as seen in adrenal ganglioneuroma (35). Excision is necessary despite the slow rate of growth, because of compressive local symptoms such as Claude-Bernard-Horner syndrome (ptosis, myosis, facial anhidrosis and flushing) (36).
The prognosis is good but surgery is needed first because of the many alternative diagnoses concerning cervical masses (carotid body tumor, ectopic parathyroid, ectopic thyroid) that cannot be identified without adequate pathological examination and second, due to tumor-related vagus/hypoglossal nerve damage or Horner syndrome (which otherwise has been described also as a complication of neoplasia removal) risk which may aggravate the overall clinical picture and associated permanent damage (37,38). Resection of head and neck, pelvis or mediastinal ganglioneuromas has a higher risk of post-operative complications when compared to adrenal ganglioneuromas while the presentation depends on the local anatomy (39).
6. Ganglioneuroma as adrenal incidentaloma
The imaging findings of an adrenal ganglioneuroma as an incidentaloma is not rare, resulting less from tumor-related complications, but more from non-tumor associated elements that require an abdominal ultrasound or an abdominal computed tomography/magnetic resonance imaging (40,41). The examination of adrenal glands represents a standard routine procedure during abdominal ultrasound both in children and adults (42). The detection of an asymptomatic adrenal ganglioneuroma may be conducted later during adult life, but generally adult tumors that are diagnosed as a true adrenal incidentaloma (non-functioning tumor with a low rate of growth, without suspected malignancy) are not referred for surgery by endocrinologist since the incidence of an adrenal incidentaloma is age dependent and they generally involve a low index of suspected aggressive behavior (43,44).
A study on 1,784 patients admitted between 2002 and 2015 for adrenalectomy showed that for 1.9% of the patients who were confirmed with ganglioneuroma (mean age of 33.4 years) that pre-contrast Hounsfield units (HU) at pre-operative computed tomography and higher post-contrast phase attenuation are suggestive for a ganglioneuroma in association with well-shaped margins (3). Nevertheless, an adrenal incidental finding in the pediatric population requires a complete endocrine panel of investigation and subsequently the patient is referred for adrenalectomy as there is no ‘true’ incidentaloma (a tumor underlying a cortical adenoma) at this segment of age (44).
7. Pediatric adrenalectomy
Subtotal adrenal resection is performed by some centers; otherwise, it is not a standard of approach (3). A study of 808 patients with neuroblastic tumors who underwent an adrenalectomy between 2000 and 2010 identified 162 cases of ganglioneuroma (20%); 70% of the ganglioneuromas had complete removal, the others had a subtotal resection that seemed safe for a median follow-up of 44 months after surgery (3). Since the degree of tumor differentiation cannot be exactly known before adrenalectomy (meaning that the tumor may be a neuroblastoma or a ganglioneuroblastoma), complete excision is encouraged (45).
A retrospective study in 2020 on 50 subjects (6/50 were ganglioneuromas) with a mean age of 4.8 years who underwent an adrenalectomy between 2007 and 2017 showed that the decision of surgery (laparotomy, which was more frequently used vs. laparoscopy) was based on tumor size at imaging assessment and image defined risk factors (IDRFs) (46). In one study from the Mayo Clinic focusing on pediatric surgery between 1993 and 2012, surgery performed for different endocrine conditions found in 241 cases aged less than 19 years, one case of ganglioneuroma (47). The adrenalectomies performed for various tumors were either laparoscopic or open (47).
Minimal access adrenal surgery (MAAS) is the standard for pediatric adrenal surgery in centers with large experience in laparoscopy (48). A multi-centric, retrospective European study between 2002 and 2013 included 68 children with a mean age of 5.2 years (3/68 were ganglioneuromas); 92.6% of the studied population had a trans-peritoneal access and 7.4% had a retro-peritoneal access while conversion to open approach was not needed (49). Laparoscopic approach represents a good alternative to standard open approach in children, but it requires a specific pediatric experience independent of tumor pre-operative features (50). Anterior vs. retroperitoneal approach is indicated in large tumors and in subjects with smaller retroperitoneal space (51). Currently, the open technique is recommended, but minimally invasive surgery may be used based on the surgeon's experience and pre-operative risk stratification assessments (52).
8. Advanced biomarkers
Recently, the protein kinase B (PKB)/AKT system was detected as a tumorigenic pathway in pediatric ganglioneuroma and mechanistic target of rapamycin (mTOR) inhibition may help (53). The AKT/mTOR/S6 mechanism is related to ganglioneuroma, not neuroblastoma (54). Potential use of mTOR inhibitors is yet to be determined, possibly as pre-operative medication to reduce the tumor size in order to facilitate complete neoplasia surgical removal (53,54). Moreover, transcription factor insulinoma-associated protein 1 (INSM1) was found to be positive in aggressive neuroblastomas and ganglioneuromas, and its role as a prognostic factor is yet to be determined (55).
Other poor prognostic biomarkers are limited to the aggressive profile of neuroblastomas, not ganglioneuroma. These include epithelial-mesenchymal transition (EMT)-related pre-mRNA processing factor 19 (Prp19) (56). The Bcl-2 gene, related to programmed cell death, encodes an oncoprotein that has been suggested to help the differentiation between ganglioneuroma/neuroblastoma based on Bcl-2 immunostaining, but currently it is not considered a relevant prognostic marker (57). However, when it comes to neuroblastoma, an aggressive neural crest-derived tumor with an overall survival rate of less than 50%, several abnormal signal transduction pathways have been identified including: TP53, ALT, ADAM22, ATRX, GAL, RAS/MAPK, KLHL13, β3-adrenergic receptor, and TWIST1 (58,59). HuC/D, an RNA binding protein, may be a marker of neuroblastic cells but not a distinctive factor between neuroblastoma/ganglioneuroma (60). Tyrosine hydroxylase (TH) has been used as a sympathoadrenal marker for tumors originating from the neural crest, and currently Phox2B has been confirmed to be a better marker especially for undifferentiated neuroblastoma and cases with negative TH expression (61).
Another novel imaging biomarker is the use of the apparent diffusion coefficient (ADC) derived from magnetic resonance quantitative analysis in cases with neuroblastic tumors to improve the assessment in the absence of surgery or pre-operatively (62).
9. Future considerations
Several aspects are still an open subject concerning the field of ganglioneuroma. One is related to the complex panel of risk factors related to tumor appearance. Whether or not maternal and intra-fetal exposure to different endocrine disruptors may be a contributor to early tumorigenesis is yet unknown (63). There is also a need for developing scoring systems for adequate management which is a relatively difficult issue since the level of statistical evidence is heterogeneous due to the rarity of the tumor (64). Another aspect is the fact that, except for symptomatic or hormonally active cases and situations where imaging follow-up shows a certain rate of tumor growth, tumor removal may not seem imperious; however, until complete histological evaluation and profiling of the lesion are conducted, a malignancy cannot be otherwise excluded. Thus, the importance of, not only a positive diagnosis, but also of a differential diagnosis as provided after surgery in adrenal as well as non-adrenal ganglioneuroma cases, must be stressed (65).
In regards to pediatric adrenalectomy, the skill and experience of the surgeon represent the key factors by which to select the procedure. Thus, there are no clear-cut general recommendations (66-68). In contrast to this, the same procedure in adults has an excellent outcome using the laparoscopic approach which is preferred in most situations, except for very large, potentially malign, invasive adrenal masses (66-68). It is well known that the term ‘adrenal incidentaloma’ which is mostly associated with an adrenocortical adenoma in adults, is controversial in children as tumors such as ganglioneuroma may embrace this scenario; however, tumor removal seems essential in this situation, in contrast to adult adrenal incientaloma, which requires in most cases just a periodic endocrine assessment and serial imaging follow-up (69-71).
10. Conclusions
Pediatric adrenal ganglioneuroma represents a tumor with a good prognosis if adequately treated. However, its recognition requires adrenalectomy which is associated with a good outcome when compared to other surgical procedures for non-adrenal ganglioneuromas. A syndromic context makes the overall outcome more severe. Further development of specific biomarkers is needed.
Acknowledgements
Not applicable.
Availability of data and materials
Not applicable.
Authors' contributions
FS drafted the manuscript and critically revised the final form. MCD researched the literature and is the corresponding author. AP researched the literature, and MC drafted the manuscript and revised the content. RCP revised the final form in light of the literature data and wrote the conclusions. AMO researched the literature, and AG approved the final form after reviewing all of the literature findings. All authors read and approved the final manuscript for publication.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
ReferencesJarzembowskiJANew prognostic indicators in pediatric adrenal tumors: Neuroblastoma and adrenal cortical tumors, can we predict when these will behave badly?1362564120203318372410.1016/j.path.2020.08.002CarsoteMGhemigianATerzeaDGheorghisan-GalateanuAAValeaACystic adrenal lesions: Focus on pediatric population (a review)9051220172824649010.15386/cjmed-677LeeJHChaiYJKimTHChoiJYLeeKEKimHYYoonYSKimHHClinicopathological features of ganglioneuroma originating from the adrenal glands402970297520162743131910.1007/s00268-016-3630-yDhanasekarKVisakanVTahirFBalasubramanianSPComposite phaeochromocytomas-a systematic review of published literature. Langenbecks Arch Surg: Mar 2, 2021 (Epub ahead of print).LamAKUpdate on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours2821322720172847731110.1007/s12022-017-9484-5MylonasKSSchizasDEconomopoulosKPAdrenal ganglioneuroma: What you need to know?537337720172908582710.12998/wjcc.v5.i10.373BurroughsMA JrUritsIViswanathOKayeADHasoonJAdrenal ganglioneuroma: A rare tumor of the autonomic nervous system12e1239820203353215810.7759/cureus.12398SpinelliCRossiLBarbettaAUgoliniCStrambiSIncidental ganglioneuromas: A presentation of 14 surgical cases and literature review3854755420152550184110.1007/s40618-014-0226-yFliednerSMJWinkelmannPERWesleyRVontheinRLehnertHGanglioneuromas across age groups: Systematic review of individual patient data94122320213270277910.1111/cen.14297SargarKMKhannaGHulett BowlingRImaging of nonmalignant adrenal lesions in children371648166420172901974510.1148/rg.2017170043BurnsAJSullivanKMKohEKTretiakovaMSZernNKDopamine secreting adrenal tumor-ganglioneuroma rather than pheochromocytoma: Case report92204221020203344757210.21037/gs-20-475EremCFidanMCivanNCobanogluUKangulFNuhogluIAlhanEHormone-secreting large adrenal ganglioneuroma in an adult patient: A case report and review of literature23646920142370563010.3109/08037051.2013.796103Escudero-FernandezJMGarcia-CarpinteroASDelgado-AlvarezICastellote-AlonsoAVázquez-MendezEJBrain paraneoplastic syndromes in a patient with mediastinal ganglioneuroma152059206220203294410010.1016/j.radcr.2020.08.010ShaoMZhangWNiuZChenSJiaYAnYZhuFWangJComputed tomography characteristics of adrenal ganglioneuroma: A retrospective analysis of 30 pathologically-confirmed cases4830006052094551020203317650810.1177/0300060520945510KulatungeCRSonHFalse-positive 123I-MIBG scintigraphy due to multiple focal nodular hyperplasia3897697820132415261610.1097/RLU.0000000000000234FendlerWPMelzerHIWalzCvon SchweinitzDCoppenrathESchmidIBartensteinPPflugerTHigh ¹²³I-MIBG uptake in neuroblastic tumours indicates unfavourable histopathology401701171020132385745810.1007/s00259-013-2491-yShawaHElsayesKMJavadiSMoraniAWilliamsMDLeeJEWaguespackSGBusaidyNLVassilopoulou-SellinRJimenezCHabraMAAdrenal ganglioneuroma: Features and outcomes of 27 cases at a referral cancer centre8034234720142403360610.1111/cen.12320YangSCaiSMaXZengQQinHHanWPengXWangHDiscrimination of histopathologic types of childhood peripheral neuroblastic tumors based on clinical and biological factors81092420183002651610.1038/s41598-018-29382-xŞirazÜGÖkdemirDDirekGAkınLHatipoğluNKendirciMKurtoğluSROHHAD syndrome, a rare cause of hypothalamic obesity: Report of two cases1038238620182955304210.4274/jcrpe.0027Ibáñez-MicóSMarcos OltraAMde Murcia LemauvielSRuiz PrunedaRMartínez FerrándezCDomingo JiménezRRapid-onset obesity with hypothalamic dysregulation, hypoventilation, and autonomic dysregulation (ROHHAD syndrome): A case report and literature review3261662220172734001810.1016/j.nrl.2016.04.008(In English, Spanish)ÖzcanGÖzsuEŞiklarZÇobanoğluNA rare cause of sleep-disordered breathing: ROHHAD syndrome857322720203333027310.3389/fped.2020.573227StoweRCAfolabi-BrownOPulmonary hypertension and chronic hypoventilation in ROHHAD syndrome treated with average-volume assured pressure support325325620193285133110.1002/ped4.12168AbaciACatliGBayramEKorogluTOlgunHNMutafogluKHizASCakmakciHBoberEA case of rapid-onset obesity with hypothalamic dysfunction, hypoventilation, autonomic dysregulation, and neural crest tumor: ROHHADNET syndrome19e12e1620132318695610.4158/EP12140.CRHarvengtJGernayCMastouriMFarhatNLebrethonMCSeghayeMCBoursVROHHAD(NET) syndrome: Systematic review of the clinical timeline and recommendations for diagnosis and prognosis105dgaa24720203240753110.1210/clinem/dgaa247BarclaySFRandCMBorchLANguyenLGrayPAGibsonWTWilsonRJGordonPMAungZBerry-KravisEMRapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD): Exome sequencing of trios, monozygotic twins and tumours1010320152630295610.1186/s13023-015-0314-xFangCWWangJSWuTTLinJTOccurrence of paratesticular ganglioneuroma 18 years after concurrent adrenal ganglioneuroma and papillary thyroid carcinoma-a case report19126520193188852110.1186/s12885-019-6440-4WikieraBNocoń-BohuszJGodzińskiJNoczyńskaAGanglioneuroma in a patient with turner syndrome19115118201325577900ShiohamaTFujiiKHinoMShimizuKOhashiHKambeMNakataniYMitsunagaTYoshidaHOchiaiHShimojoNCoexistence of neuroblastoma and ganglioneuroma in a girl with a hemizygous deletion of chromosome 11q14.1-23.3170A49249720162646389310.1002/ajmg.a.37430DemirHAOzdelSKaçarASenelEEmirSTunçBGanglioneuroma in a child with hereditary spherocytosis54187190201222734309RodriguezEFJonesRMillerDRodriguezFJNeurogenic tumors of the mediastinum3717918620203244859210.1053/j.semdp.2020.04.004SandruFCarsoteMValeaAAlbuSEPetcaRCDumitrascuMCSomatostatinoma: Beyond neurofibromatosis type 1 (review)203383338820203290500210.3892/etm.2020.8965WilliamsAJDohertyESHartMHGriderDJDiffuse gastric ganglioneuromatosis: Novel presentation of PTEN hamartoma syndrome-case report and review of gastric ganglioneuromatous proliferations and a novel PTEN gene mutation2018431981820182977014910.1155/2018/4319818AlGhamdiMHAlAyedAAlShabyliNAAlGhamdiNHAl RasheedMConcurrent adrenal and extra-adrenal ganglioneuromas: A case report201817182020193180686110.12659/AJCR.918568XuTZhuWWangPCervical ganglioneuroma: A case report and review of the literature98e1520320193098571510.1097/MD.0000000000015203JacksonJRTranHCSteinJEShimadaHPatelAMMarachelianAKimESThe clinical management and outcomes of cervical neuroblastic tumors20410911320162745187510.1016/j.jss.2016.04.030KifluWNegussieTGanglioneuroma of the neck: A case report556971201729148641GarzorzNDiercksGRLinHWFaquinWCRomoLVHartnickCJA case of pediatric parapharyngeal space ganglioneuroma95E16E20201627140023BakshiJMohammedAWLeleSNadaRGanglioneuromas involving the hypoglossal nerve and the vagus nerve in a child: Surgical difficulties95E22E2420162693033910.1177/014556131609500207WuZZengQZhangXTuSZhangFGanglioneuroma in unusual sites: Clinical, radiologic and pathological features1148624866201831949561ZvizdicZHaxhijaEChikhaAMilisicEJonuziAVranicSLaparoscopic extirpation of adrenal gland ganglioneuroma incidentally diagnosed during evaluation for patchy alopecia areata in an adolescent boy2848548920193089757410.1159/000499755KanthanRSengerJLKanthanSThree uncommon adrenal incidentalomas: A 13-year surgical pathology review106420122254032410.1186/1477-7819-10-64SłapaRZJakubowskiWSDobruch-SobczakKKasperlik-ZałuskaAAStandards of ultrasound imaging of the adrenal glands1537738720152680729510.15557/JoU.2015.0035IchijoTUeshibaHNawataHYanaseTA nationwide survey of adrenal incidentalomas in Japan: The first report of clinical and epidemiological features6714115220203169499310.1507/endocrj.EJ18-0486FassnachtMArltWBancosIDralleHNewell-PriceJSahdevATabarinATerzoloMTsagarakisSDekkersOMManagement of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors175G1G3420162739002110.1530/EJE-16-0467DecarolisBSimonTKrugBLeuschnerIVokuhlCKaatschPvon SchweinitzDKlingebielTMuellerISchweigererLTreatment and outcome of ganglioneuroma and ganglioneuroblastoma intermixed1654220162746502110.1186/s12885-016-2513-9HeWGYanYTangWCaiRRenGClinical and biological features of neuroblastic tumors: A comparison of neuroblastoma and ganglioneuroblastoma8377303773920172846548010.18632/oncotarget.17146KundelAThompsonGBRichardsMLQiuLXCaiYSchwenkFWLteifANPittockSTKumarSTebbenPJPediatric endocrine surgery: A 20-year experience at the mayo clinic9939940620142442328610.1210/jc.2013-2617EmreŞÖzcanRBakırACKuruğoğluSÇomunoğluNŞenHSCelkanTTekantGTAdrenal masses in children: Imaging, surgical treatment and outcome4320721220203096201810.1016/j.asjsur.2019.03.012Fascetti-LeonFScottonGPioLBeltràRCaionePEspositoCMattioliGSaxenaAKSarnackiSGambaPMinimally invasive resection of adrenal masses in infants and children: Results of a European multi-center survey314505451220172855036610.1007/s00464-017-5506-0Rodríguez IglesiasPGómez-Chacón VillalbaJRodríguez CaraballoLOrtolá FortesPCortés SáezJMarco MaciánAVila CarbóJJLaparoscopic adrenalectomy: Advantages of the minimally invasive approach29162165201628481069(In Spanish)EassaWEl-SherbinyMJednakRCapolicchioJPThe anterior approach to retroperitoneoscopic adrenalectomy in children: Technique8353920122123673310.1016/j.jpurol.2010.12.007ElHaddadACastellaniCSorantinEBeneschMKampelmühlerESingerGTillHMinimally invasive surgery for pediatric adrenal masses-report on four cases7e75e7820193168152910.1055/s-0039-1694058TaoTShiHDurbinADLookATTargeting ganglioneuromas with mTOR inhibitors8185662120213355360910.1080/23723556.2020.1856621TaoTShiHWangMPerez-AtaydeARLondonWBGutierrezALemosBDurbinADLookATGanglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors217e2019187120203272870010.1084/jem.20191871WangHKrishnanCCharvilleGWINSM1 expression in peripheral neuroblastic tumors and other embryonal neoplasms2244044820193097503210.1177/1093526619843725CaiYChenKChengCXuYChengQXuGWuYWuZPrp19 is an independent prognostic marker and promotes neuroblastoma metastasis by regulating the hippo-YAP signaling pathway1057536620203322487810.3389/fonc.2020.575366FetahuISTaschner-MandlSNeuroblastoma and the epigenome4017318920213340485910.1007/s10555-020-09946-yLiuZGrantCNSunLMillerBASpiegelmanVSWangHGExpression patterns of immune genes reveal heterogeneous subtypes of high-risk neuroblastoma12173920203262985810.3390/cancers12071739DengJJiangPYangTHuangMQiWZhouTYangZZouYGaoGYangXTargeting β3-adrenergic receptor signaling inhibits neuroblastoma cell growth via suppressing the mTOR pathway51429530020193103094510.1016/j.bbrc.2019.04.099TakemotoJKudaMKohashiKYamadaYKogaYKinoshitaISouzakiRTaguchiTOdaYHuC/D expression in small round cell tumors and neuroendocrine tumors: A useful tool for distinguishing neuroblastoma from childhood small round cell tumors8516216720193046880110.1016/j.humpath.2018.11.004WarrenMMatsunoRTranHShimadaHUtility of Phox2b immunohistochemical stain in neural crest tumours and non-neural crest tumours in paediatric patients7268569620182898698910.1111/his.13412Cerdá AlberichLSangüesa NebotCAlberich-BayarriACarot SierraJMMartínez de Las HerasBVeiga CanutoDCañeteAMartí-BonmatíLA confidence habitats methodology in MR quantitative diffusion for the classification of neuroblastic tumors12385820203337121810.3390/cancers12123858AhmedKEMFrøysaHGKarlsenOABlaserNZimmerKEBerntsenHFVerhaegenSRopstadEKellmannRGoksøyrAEffects of defined mixtures of POPs and endocrine disruptors on the steroid metabolome of the human H295R adrenocortical cell line21832833920193047676410.1016/j.chemosphere.2018.11.057PicardCOrbachDCartonMBrugieresLRenaudinKAubertSBerrebiDGalmicheLDujardinFLeblondPRevisiting the role of the pathological grading in pediatric adrenal cortical tumors: Results from a national cohort study with pathological review3254655920193040194610.1038/s41379-018-0174-8MardiKThakurRCBiswasBGanglioneuroma arising from the L5 nerve root: A rare case report1023223320152639661510.4103/1793-5482.161180PaduraruDNNicaACarsoteMValeaAAdrenalectomy for Cushing's syndrome: Do's and don'ts9334341201627928434ValeaAGhervanCCarsoteMAlbuSEGeorgescuCEDifferent surgical options in Cushing's disease339432016NicaAECarsoteMPaduraruDNValeaABilateral adrenalectomy and Nelson's syndrome512822852016CarsoteMValeaADumitruNTerzeaDPetrovaEAlbuSBuruianaAGhemigianAMetastases in daily endocrine practice514784822016Araujo-CastroMIturregui GuevaraMCalatayud GutiérrezMParra RamírezPGracia GimenoPHanzuFALamas OliveiraCPractical guide on the initial evaluation, follow-up, and treatment of adrenal incidentalomas adrenal diseases group of the Spanish society of endocrinology and nutrition6740841920203234994110.1016/j.endinu.2020.03.002(In English, Spanish)MaasMNassiriNBhanvadiaSCarmichaelJDDuddalwarVDaneshmandSDiscrepancies in the recommended management of adrenal incidentalomas by various guidelines205525920213285698410.1097/JU.0000000000001342